Navigation Links
Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
Date:12/8/2009

MEDIA, Pa., Dec. 8 /PRNewswire/ -- Shepherd, Finkelman, Miller & Shah, LLP (Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">http://www.sfmslaw.com; e-mail: Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">jmiller@sfmslaw.com), a law firm with offices in California, Connecticut, Florida, New Jersey, Pennsylvania and Wisconsin, has filed a lawsuit seeking class action status in the United States District Court for the Eastern District of Pennsylvania against Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (Amex: HEB) and the Company's CEO, William A. Carter, M.D., on behalf of all purchasers of Hemispherx securities between February 18, 2009 and November 2, 2009, inclusive (the "Class Period"). A copy of the Complaint filed in this action can be obtained from the Court, or you can call our offices toll free at either 866/540-5505 or 877/891-9880 to speak with an attorney regarding this matter and we will send you a copy of the Complaint.

The Complaint alleges that the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically, the Complaint alleges that, throughout the Class Period, the Company issued a series of materially false and misleading statements to the market concerning the status of its application for approval by the U.S. Food and Drug Administration ("FDA") of Ampligen, its experimental drug for the treatment of Chronic Fatigue Syndrome. While the market understood that the Company's application was complete and that any delays in FDA action were due to constraints on the FDA's resources, the Company took advantage of the inflated stock price to, among other things, raise millions of dollars in two public stock offerings.

On November 2, 2009, the Company announced that it still needed to submit additional information to the FDA, and revealed that it had already submitted six previously undisclosed reports to the FDA. As noted by market observers, this news stood in stark contrast to Class Period statements regarding the supposed status of Hemispherx's New Drug Application ("NDA"). As a result of this revelation, shares of Hemispherx's common stock closed at $1.33 per share on November 2, 2009, down $0.12 per share, and fell even more precipitously the next day, closing at $1.13 per share, well below the Class Period high of $3.75 per share reached on June 4, 2009. On December 1, 2009, Hemispherx announced that its NDA had been rejected by the FDA.

If you purchased Hemispherx securities between February 18, 2009 and November 2, 2009 (inclusive), you may qualify to serve as lead plaintiff on behalf of the Class. All motions for appointment as a lead plaintiff must be filed with the Court by no later than January 11, 2010. Any member of the proposed Class may move the Court to serve as lead plaintiff in this action through counsel of their choice, or may remain an absent Class member. There are certain legal requirements to serve as lead plaintiff, which we would be pleased to discuss with you. Please contact James E. Miller, Esquire (866/540-5505; Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">jmiller@sfmslaw.com) or James C. Shah, Esquire (877/891-9880; Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">jshah@sfmslaw.com), if you would like to discuss this action or have any question regarding this notice or your rights.

Shepherd, Finkelman, Miller & Shah, LLP (Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">http://www.sfmslaw.com) is a law firm that represents investors, including institutions and individuals, as well as consumers, in class action and other complex litigation, and maintains offices in California, Connecticut, Florida, New Jersey, Pennsylvania and Wisconsin. The firm's attorneys have appeared in matters on behalf of our clients throughout the United States and have been appointed lead counsel in a number of class actions and corporate governance matters.

SOURCE Shepherd, Finkelman, Miller & Shah, LLP


'/>"/>
SOURCE Shepherd, Finkelman, Miller & Shah, LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MICROS to Present at Wachovia Securities 1st Annual Services Conference
2. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
3. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
4. RxElite Files Registration Statement with Securities and Exchange Commission
5. Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation
6. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
7. Genomic Health to Present at JMP Securities Healthcare Focus Conference
8. Wolf Popper Announces Filing of Securities Class Action Lawsuit Against Medtronic Inc. - MDT
9. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
10. American Stock Exchange LLC to Delist Securities of AMS Health Sciences, Inc.
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Sector Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. ... big data solutions, today announced that its MyDario product is expected to ... TV listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, ... ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical (AVACEN) ... is now successfully helping those with the widespread pain ... Fibromyalgia diagnosed Amanda in Essex, England ... washing my hair, experiencing no sleep at all, tremendous ... spasm… I cannot recommend [the AVACEN 100] enough, how ...
(Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
Breaking Medicine Technology: